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Background/aim: F2α-isoprostane is accepted as an oxidative stress indicator and melatonin shows neuroprotective effects by
antioxidative and antiamyloidogenic influences. By measuring these in patients diagnosed with minimal cognitive impairment (MCI)
and Alzheimer-type dementia, we intended to demonstrate whether the measurement of these markers contributes to early diagnosis of
Alzheimer disease (AD) in the MCI stage or not.
Materials and methods: Three groups (n = 63) were created: the AD group, MCI group, and control group. Serum melatonin levels
were measured by radioimmunoassay method, and plasma total 8-isoPGF2α levels were measured by enzyme immunoassay method.
Results: Significant differences were observed in the melatonin levels between the MCI group and AD group (P = 0.009), and in
8-isoPGF2α levels between the AD group and control group (P = 0.022). A negative correlation between mini-mental state examination
(MMSE) scores and 8-isoPGF2α levels (r = –0.459, P < 0.001) and positive correlation between MMSE scores and melatonin levels (r =
0.317, P = 0.011) were found.
Conclusion: Although the plasma 8-isoPGF2α and serum melatonin levels in MCI were not found to be good early diagnostic markers
to indicate risk of AD, results were found to support the role of oxidative stress in AD.
Key words: Alzheimer disease, minimal cognitive impairment, oxidative stress, isoprostane, melatonin

1. Introduction
Alzheimer disease (AD) is a progressive neurodegenerative
disorder characterized by cognitive impairment. Before
AD diagnosis, there is a long period with neuropathological
changes (1–3).
Minimal cognitive impairment (MCI) is the clinical
status of nondemented individuals who have memory
deficits confirmed by objective tests. These memory
deficits should not impair entire cognitive function or
daily living activities (2). Annual conversion rate of MCI
to dementia is reported as 10%–15% in different studies
(4). The degenerative neuropathology of AD in the brain
starts 20–30 years earlier than the clinical onset (5). Thus,
MCI state is an important stage to determine and treat in
people who are at risk of developing dementia.
Oxidative damage is present in early AD and also in
MCI, and the role of oxidative stress is suggested in the
etiopathogenesis of AD. When the balance between
oxidant and antioxidant status shifts to the oxidant side,
* Correspondence: burcufenercioglu@yahoo.com

oxidative stress manifests itself in the form of protein
oxidation, DNA oxidation, and lipid peroxidation (6). Due
to high polyunsaturated fatty acid content of brain, which
is sensitive to oxidative stress, primarily lipid peroxidation
occurs in the brain (7–9).
Isoprostanes, prostaglandin isomers, are considered to
be the most accurate indicators of oxidative stress (10). In
vitro and in vivo measurements of isoprostane are sensitive
and specific for lipid peroxidation (11). Isoprostane
F2α-III and 8-isoprostaglandin F2α are major products
formed by free radical-catalyzed peroxidation of esterified
arachidonic acid in membrane phospholipids (12).
The other parameter focused on is melatonin, which
is suggested as an important direct free radical scavenger
and indirect antioxidant (13–16). Melatonin is shown to
be significantly effective at reducing oxidative damage
in experimental models of the brain (15). In addition to
reduced melatonin secretion during aging, more prominent
decreases are reported in dementia (13,17). Daytime
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and nighttime melatonin levels are found to be lower in
those aged 60 and above than in younger individuals, and
patients with AD are also shown to have lower melatonin
levels than individuals without the disease (13,18).
In this study we analyzed the plasma 8-isoPGF2α
levels and serum melatonin levels in nondemented
control individuals and in patients diagnosed with MCI
and Alzheimer-type dementia in order to demonstrate
whether the measurement of these markers contributes to
early diagnosis in the MCI stage or not.
2. Materials and methods
The study was conducted with the cooperation of
the Biochemistry and Psychiatry Departments of the
Süleyman Demirel University Medicine Faculty (Isparta,
Turkey). The study protocol was approved by the Süleyman
Demirel University Board of Ethics.
2.1. Subjects
Subjects older than 60 years of age (n = 63) from among
residents of Isparta Atabey Rest Home, admissions to the
Psychiatry Department, and field research were recruited
to the study consecutively after a systematic physical and
psychiatric examination by a psychiatry doctor.
For the assessment of cognitive status, a geriatric
depression scale (19), global deterioration scale (20),
activities of daily life scale (21), clock drawing test (22),
behavioral pathology in AD scale (BEHAVE-AD) (23),
and mini-mental state examination (MMSE) (24,25)
were used. Patients whose life expectancy appeared to be
less than 3 months because of life-threatening diseases,
those taking steroids or vitamins, those whose cognitive
functions could not be assessed because of blindness
or deafness, and those with neurological or psychiatric
disorders other than dementia were excluded.
In the study, three groups were created: the AD group
(n = 20), MCI group (n = 21), and control group (n =
22). The diagnosis of MCI was established according to
the Peterson criteria (26) and the diagnosis of dementia
of the Alzheimer type was established according to DSMIV criteria (22). The patients whose MMSE score was
24 or lower were accepted as having impaired cognitive
function. The patients whose MMSE scores were higher
than 26, who had normal cognitive functions, and who did
not meet DSM-IV and Peterson diagnostic criteria were
included in the control group. The AD group consisted
of 20 patients (8 women and 12 men) with mean age of
79.05 ± 8.93 years and MMSE scores of 14.7 ± 4.3. The
MCI group consisted of 21 patients (12 women and 9 men)
with mean age of 73.95 ± 7.19 years and MMSE scores of
22.0 ± 1.3. The control group consisted of 22 individuals (9
women and 13 men) with mean age of 71.59 ± 6.65 years
and MMSE scores of 27.9 ± 1.3.
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2.2. Sample collection and preparation
After overnight fasting, between 0800 and 0900 hours
venous blood samples were drawn into EDTA-containing
tubes and polystyrene tubes. After centrifugation at 3000
× g for 10 min, plasma and serum samples were separated.
Butylated hydroxytoluene (Sigma, Germany) was added to
plasma samples, which were stored for isoprostane study
(0.5% of plasma volume). Serum and plasma samples were
stored and frozen at –80 °C until assayed.
2.3. Measurement of plasma total 8-isoPGF2α levels
Plasma total 8-isoPGF2α levels were measured using the
Direct 8-iso-Prostoglandin F2α Enzyme Immunoassay Kit,
catalog number 900-091 (Correlate, Assay Designs, USA).
2.4. Measurement of serum melatonin levels
Serum melatonin concentrations were measured using the
Melatonin Direct Radioimmunoassay (Serum/Plasma)
Kit, REF RE29301 (IBL, Germany).
2.5. Statistical analysis
Statistical analysis was performed with SPSS 11.0 for
Windows. For three-group comparison, ANOVA and
ANCOVA tests were used, and for pairwise comparisons
the post hoc Bonferroni test was used. Chi-square test
was used for comparison of sex characteristics and
Kruskal–Wallis ANOVA was used for comparison of
age characteristics in the groups. Correlations between
variables were assessed with Pearson’s correlation
coefficients (r) and Mann–Whitney U tests. Data are
expressed as mean ± standard deviation (SD). P < 0.05 was
accepted as significant.
3. Results
Melatonin levels were significantly higher in the MCI
group than in the AD group (P = 0.009). The 8-isoPGF2α
levels were significantly higher in the AD group than in the
control group (P = 0.022). A negative correlation between
MMSE scores and 8-isoPGF2α levels (r = –0.459, p <
0.001) and a positive correlation between MMSE scores
and melatonin levels was found (r = 0.317, P = 0.011).
Data were analyzed using ANCOVA and effect of age on
melatonin was not significant (F = 1.59, P = 0.960). The
results are shown in the Table.
4. Discussion
In several studies, cerebrospinal fluid (CSF) isoprostanes in
patients with postmortem definitive diagnosis of AD and
also plasma and urinary isoprostanes in living probable
AD patients were measured. Elevated isoprostanes in
the brain and CSF obtained during autopsy of patients
diagnosed with AD have been reported (27,28). However,
postmortem studies could not define whether the high
isoprostane levels in CSF represent an early step in the
neurodegeneration process as a result of oxidative stress by
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Table. Age and 8-isoPGF2α and melatonin levels in study groups.
Control group

MCI group

AD group

Age

71.59 ± 6.65

73.95 ± 7.19

79.05 ± 8.93a

8-isoPGF2α (pg/mL)

2014.9 ± 809.1

2580.7 ± 1239.7

3254.8 ± 2066.1b

Melatonin (pg/mL)

11.88 ± 2.35

12.73 ± 5.57

9.02 ± 2.91c*

Data are given as mean ± SD.
a: Significant difference when compared to control group (P = 0.006).
b: Significant difference when compared to control group (P = 0.022).
c: Significant difference when compared to MCI group (P = 0.009).
*: Effect of age on melatonin was not significant (ANCOVA, F = 1.59, P = 0.96).

lipid peroxidation or the final event. An increase in plasma
or urine F2-isoprostanes in patients with AD or MCI has
also been reported (29–31). However, in the literature
there are conflicting findings in CSF, peripheral plasma,
and urine F2-isoprostane levels in living individuals
with clinically diagnosed AD (32,33). In addition, it
was suggested in a recent study that the CSF levels of
F2-isoprostanes and beta-amyloid 1-42 are associated
with the severity of neuropsychological symptoms, and
also that the median levels of F2-isoprostane and F4neuroprostanes were significantly higher in the cognitive
impairment group than the control group (34).
In our study, a statistically negative correlation between
MMSE scores and plasma
8-isoPGF2α levels suggests that an increase in oxidative
stress might be associated with cognitive decline. Plasma
8-isoPGF2α levels of both the AD and MCI groups
were higher than in the control group, but statistical
significance was found only between the AD group and
control group. The MCI group diagnosed clinically needs
to be determined precisely. Patient selection criteria, assay
method type, and the effect of additional diseases in elderly
patients can alter the results of studies.
In addition to its major role in the regulation of circadian
rhythms, the antioxidative and neuroprotective roles of
melatonin in preventing the accumulation of amyloid have
been demonstrated. In AD patients and elderly people, low
melatonin values and impaired melatonin rhythm have
also been shown. Before appearance of clinical symptoms,
the changes in melatonin may be an early event in the
development of AD (13,15,35). However, no association
was found between postmortem CSF melatonin levels
and the onset, duration, and severity of disease (17).
Ventricular CSF melatonin levels were determined in
patients with postmortem neuropathological staging
and it was suggested that the decrease in CSF melatonin
levels might be an early event in the development of AD
(36). Wu et al. investigated the correlation between CSF
and pineal melatonin content and plasma-CSF melatonin
levels and suggested melatonin as an early marker in AD
due to decreased melatonin levels since the earliest stage

of AD (37). On the other hand, recent clinical studies
suggested melatonin use for the preventive treatment
of major neurodegenerative disorders (38). Wade et al.
investigated the addition of prolonged-release melatonin
to conventional anti-AD therapy (acetylcholinesterase
inhibitor with or without memantine) and determined
cognitive function improvement in mild to moderate AD
cases (39).
In our study, both the control group and MCI group
mean serum melatonin levels were higher than in the AD
group. However, a significant difference was only found
between the MCI and AD groups; the differences between
the AD and control and the MCI and control groups were
not significant. Existence of a positive correlation between
MMSE score and levels of melatonin shows a protective
effect in terms of cognitive status. Absence of a significant
difference between the AD and control group, slightly
higher mean melatonin levels in the MCI group compared
to the control group, and the coincidence of values in the
data from the three groups suggest that serum melatonin
levels are not predictive in the MCI stage.
In our study, the levels of melatonin were measured
only in the morning. In several studies, nocturnal
melatonin levels in AD have shown selective decrease
(40,41). However, during the day, increased melatonin
levels were also shown. In melatonin production, in
addition to the changes with age, time changes in the
rhythm of melatonin are reported (37,42). Pineal gland
size and melatonin secretion of individuals has also been
determined genetically (13). Perhaps especially in MCI
individuals, longitudinal studies showing changes in
melatonin rhythm may be more meaningful.
As with many peripheral markers investigated for early
diagnosis of AD, our findings are limited due to other
tissue interactions and lack of specificity to the brain.
In conclusion, although the plasma 8-isoPGF2α and
serum melatonin levels in MCI were not found to be good
early diagnostic markers to show risk of AD, in combination
with other diagnostic markers these parameters may be
supportive. This study also supports the suggestions about
the role of oxidative stress in AD.
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